Charles A. McWherter

Author

Also Known As

C A McWherter, C. A. McWherter, C. McWherter, C. Mcwherter, C.A. McWherter, C.A. Mcwherter, Charles A McWherter, Charles A. McWherter, Charles A. Mcwherter, Charles McWherter

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Monsanto (United States)CymaBay Therapeutics (United States)Washington University in St. Louis University of Miami Newcastle University

About

Charles A. McWherter is an author at Monsanto (United States) specializing in medicine, natural sciences, and biochemistry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	19	838
2	Natural Sciences	12	14	648
3	Biochemistry	12	14	664
4	Engineering	3	3	248
5	Biomolecular Engineering	3	3	108

Charles A. McWherter

Publications

2.4K

Citations

H-Index

Page 1

	Year	Citations
A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis Gideon M. Hirschfield, Christopher L. Bowlus, Marlyn J. Mayo, New England Journal of Medicine	2024	192
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study David Jones, Pol Boudes, Mark G. Swain, The Lancet. Gastroenterology & hepatology Molecular PharmacologySelective Ppar-δ AgonistHepatologyBiliary TractMedicine	2017	181
Kinetic and structural evidence for a sequential ordered Bi Bi mechanism of catalysis by Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase David A. Rudnick, Charles A. McWherter, Warren J. Rocque, Journal of Biological Chemistry EngineeringMolecular BiologyChemical BiologyBiosynthesisProtein N-myristoyltransferase	1991	148
Genetic studies reveal that myristoylCoA:protein N‐myristoyltransferase is an essential enzyme in <i>Candida albicans</i> Robin A. Weinberg, Charles A. McWherter, Sandra K. Freeman, Molecular Microbiology	1995	122
A comparative analysis of the kinetic mechanism and peptide substrate specificity of human and Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase Warren J. Rocque, Charles A. McWherter, David C. Wood, Journal of Biological Chemistry Molecular BiologyChemical BiologySaccharomyces Cerevisiae Myristoyl-coaProtein SynthesisBiosynthesis	1993	108
Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study Gideon M. Hirschfield, Mitchell L. Shiffman, Aliya Gulamhusein, Hepatology	2023	101
The selective peroxisome proliferator–activated receptor‐delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice Fahrettin Haczeyni, Vanessa Barn, Auvro R. Mridha, Hepatology Communications	2017	94
Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis Andreas E. Kremer, Marlyn J. Mayo, Gideon M. Hirschfield, Liver International	2021	83
A Randomized, Double‐Blind, Active‐ and Placebo‐Controlled Efficacy and Safety Study of Arhalofenate for Reducing Flare in Patients With Gout Jeffrey E. Poiley, Alexandra Steinberg, Yun‐Jung Choi, Arthritis & Rheumatology	2016	76
A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis Christopher L. Bowlus, Michael Galambos, Richard Aspinall, Journal of Hepatology HepatologyBiliary Tract52-Week StudyGastroenterologyPathology	2022	75

Page 1